INCY - Incyte reports mixed Q4 results; initiates FY24 outlook
2024-02-13 07:10:06 ET
- Incyte press release ( NASDAQ: INCY ): Q4 Non-GAAP EPS of $1.06 misses by $0.09 .
- Revenue of $1.01B (+9.0% Y/Y) beats by $10M .
-
2024 Financial Guidance ...
Current
Jakafi net product revenues
$2,690 - $2,750 million
Other Hematology/Oncology net product revenues
$325 - $360 million
GAAP Cost of product revenues
7 – 8% of net product revenues
Non-GAAP Cost of product revenues
6 – 7% of net product revenues
GAAP Research and development expenses
$1,720 - $1,760 million
Non-GAAP Research and development expenses
$1,580 - $1,615 million
GAAP Selling, general and administrative expenses
$1,210 - $1,240 million
Non-GAAP Selling, general and administrative expenses
$1,115 - $1,140 million